2 . Our results indicate the value of peptide-wise analysis of large global proteomic analysis data units as opposed to protein-wise analysis, in which outlier differential peptides are usually neglected. Cancer-specific proteolytic activity is one of the highlights of cancer progression, and specific changes in the tumor degradosome may serve as a reservoir for potential diagnostic molecular features (1). For example , cancer-specific fragments of cytokeratins are among the most frequently tested protein-based cancer markers. Cytokeratin typing and quantitation for cancer studies, as well as diagnosis, prognosis, and therapy monitoring, have become routine in recent years (26). Moreover, keratins are cleaved in a cancer-dependent manner, and some from the keratin-based antibodies used in the context of cancer identify such fragments (7). For instance, keratins 18 and 19 are known substrates intended for caspase degradation (8) which occurs in the intermediate stage of apoptosis (6), when well-controlled proteolysis of many components of the cytoplasmic and nuclear cytoskeleton orchestrates cellular breakdown. The resulting abundant keratin fragments are released into the Tecadenoson circulation by tumor cells and can be detected there. Currently, several antibodies with epitopes linked to keratins and/or their fragments, such as tissue polypeptide antigen (TPA)1, tissue polypeptide-specific antigen, keratin 19 fragment (Cyfra211), and keratin 18 fragment (M30, M65), are widely used intended for cancer studies, and their clinical value is frequently assessed by numerous groups in different experimental settings. In the case of certain carcinomas, such as nonsmall cell lung cancer (6), oral cancer (7), bladder cancer (BC) (9), and colon cancer (10), serum assays derived from keratins 8, 18, and 19 are increasingly used to monitor tumor weight and disease progression and for the early detection of recurrence and fast assessment from the efficacy from the response to therapy (11). In addition , tumors derived from epithelial cells are known to retain the cytokeratin expression pattern characteristic from the originating cell Tecadenoson types, development, and differentiation stage (12), (13). Thus, the cytokeratin profile is indicative of a tumor’s origin and generally retained, even in mobilized cells far from the primary MMP17 source of malignancy. However , knowledge regarding the proteolytic fragments populating the plasma/serum/urine/saliva of cancer patients is very limited. A plethora of commercially available antibodies, in general of not precisely defined affinities, are used to explore the potential of protein fragments as cancer markers. Such a black-box approach lacks a precise definition of focuses on and is carried out without selection of the best fragments. In addition , antibody-based approaches suffer from cross-reactivity with other targets, leading to numerous controversies, as for instance raised in the case of keratin-based markers (1416). Tecadenoson Although cross-reactivity decreases the specificity of existing tests, many currently available kits have affordable levels of sensitivity and specificity. Assessment from the true sensitivity and specificity of cytokeratin fragment-based tests, excluding cross-reactivity phenomena, would require Tecadenoson the application of more selective methods, such as methods based on mass spectrometry. To the best of our knowledge, these methods have not yet been attempted. In the present study, we reanalyzed the data units collected during global proteomic studies of Tecadenoson adenocarcinoma (AC) and ulcerative colitis, using data obtained previously by our group (17) and those available from the MS-data PRIDE repository (18), focusing on disease-specific proteolytic events. In addition to detecting peptides resulting from the caspase cleavage of keratins in AC, we recognized other disease-specific proteolytic cleavages in a wider set of proteins. In some cases, the resulting peptides are an order of magnitude more abundant in cancer than in control noncancerous tissue, whereas the large quantity ratio for a caspase-cleaved keratin 18 peptide is only a few. The cleavage pattern of peptides detected in cancer tissue revealed a strong preference for V, I, A, T, and C residues at the P1 cleavage site (VIATC consensus), making neutrophil elastase the most probable candidate for the protease responsible for the noticed cancer-specific cleavage. In result, by reanalyzing the existing data sets we identified a new class of cancer-specific protein fragments that are potential markers of the presence and progression of cancer..